Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2025

Q2 2025 biggest moves
  • ALHCALHC

    Alignment Healthcare

    Cut 93%

    now 0.1% of portfolio

  • UTHRUTHR

    United Therapeutics

    Added 96%

    now 2.8% of portfolio

  • MRKMRK

    Merck

    New

    1.2% of portfolio

  • DVAXDVAX

    DYNAVAX TECHNOLOGIES

    Sold out

    was 1.3% of portfolio

129 changes in all

Top Holdings124 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

18M$1.4B24.9%——
16 qtrssince 2021-Q3
Unchanged
0
OSCR

Oscar Health, Inc.

11.6M$249.8M4.5%$11.50+64.56%
7 qtrssince 2023-Q4
Decreased
0
VTRS

Viatris Inc.

24M$214.5M3.9%$11.16-23.56%
19 qtrssince 2020-Q4
Increased
56
MRUS
MRUSDelisted

MERUS N V

3.4M$178M3.2%——
15 qtrssince 2021-Q4
Increased
60
CNC

Centene Corporation

3.2M$172.9M3.1%$65.72-17.41%
23 qtrssince 2019-Q4
Increased
66
174.4M$172.9M3.1%——
6 qtrssince 2024-Q1
Unchanged
0
SPRY

ARS Pharmaceuticals, Inc.

9.7M$169.7M3.1%$8.53+104.57%
11 qtrssince 2022-Q4
Decreased
0
INDV
INDVDelisted

INDIVIOR PLC

10.6M$155.8M2.8%$8.28+38.06%
4 qtrssince 2024-Q3
Unchanged
0
UTHR

United Therapeutics Corporation

540,626$155.3M2.8%$298.00-3.57%
2 qtrssince 2025-Q1
Increased
83
NBIX

Neurocrine Biosciences, Inc.

1.2M$146.8M2.7%$107.41+17.02%
18 qtrssince 2021-Q1
Decreased
0
110M$143.2M2.6%——
4 qtrssince 2024-Q3
Unchanged
0
RVMD

Revolution Medicines, Inc.

3.4M$124.5M2.3%$28.19+30.53%
22 qtrssince 2020-Q1
Increased
53
70M$124.2M2.3%——
5 qtrssince 2024-Q2
Unchanged
0
BKD

Brookdale Senior Living Inc.

15.4M$106.9M1.9%$4.41+57.81%
23 qtrssince 2019-Q4
Decreased
0
LEGN
LEGN
ADR

Legend Biotech Corporation

3M$105.1M1.9%$33.84+4.86%
3 qtrssince 2024-Q4
Increased
70
PFE

Pfizer, Inc.

4.3M$104.4M1.9%$22.39-1.97%
2 qtrssince 2025-Q1
Increased
59
AHCO

AdaptHealth Corp.

9.9M$93.4M1.7%$17.88-47.25%
23 qtrssince 2019-Q4
Increased
48
NAMS

NewAmsterdam Pharma Company N.V.

5.1M$92.6M1.7%$23.65-23.41%
6 qtrssince 2024-Q1
Increased
58
IDYA

IDEAYA Biosciences, Inc.

3.9M$82.3M1.5%$21.08-0.30%
12 qtrssince 2022-Q3
Increased
56
VERA

Vera Therapeutics, Inc.

3.3M$78.9M1.4%$23.70-0.61%
2 qtrssince 2025-Q1
Increased
76
$5.5B
AUM
124
Positions
Q2 2025
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2024-Q1$5,748,069,8946.13835504533%
2024-Q2$6,010,510,6294.56571927342%
2024-Q3$6,692,805,83111.3517011135%
2024-Q4$5,280,006,191-21.1092279632%
2025-Q1$5,064,779,427-4.07625969013%
2025-Q2$5,509,809,2648.78675652937%
Activity profile
$ moved · Q2'25
New20%Increased31%Decreased21%Exited29%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.4 years
<1Q16%1-4Q0%1-2Y25%2Y+59%

Deerfield Management Company, L.P. manages $5.5B across 124 positions as of Q2 2025. Top holdings: NUVL (24.9%), OSCR (4.5%), VTRS (3.9%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$6B
NUVL24.91%
OSCR4.53%
VTRS3.89%
MRUS3.23%
CNC3.14%
INTEGRA LIFE3.14%
SPRY3.08%
INDV2.83%
UTHR2.82%
NBIX2.66%
Other2.60%

Portfolio allocation by GICS sector

Sectors4
Healthcare99.46%
Real Estate0.45%
Unknown0.08%
Financial Services0.00%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used